Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey
Immune checkpoint inhibitors (ICI) block negative regulatory molecules, such as CTLA-4, PD-1 and PD-L1, in order to mount an antitumor response. T cells are important for antiviral defense, but it is not known whether patients with cancer treated with ICI are more or less vulnerable to viral infecti...
Saved in:
| Main Authors: | Anne R Bass, Karmela K Chan, Nilasha Ghosh, Aidan Tirpack |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001550.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aggravating factors and post COVID-19 conditions in COVID-19 patients complicated with autoimmune rheumatic diseases
by: Yoshihiko Ikeno, et al.
Published: (2024-12-01) -
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01) -
Predictive Factors for COVID-19 Severity in Patients with Axial Spondyloarthritis: Real-World Data from the Romanian Registry of Rheumatic Diseases
by: Andreea-Iulia Vlădulescu-Trandafir, et al.
Published: (2025-02-01) -
Rare Complication of Pneumomediastinum and Pneumopericardium in a Patient with COVID-19 Pneumonia
by: Anshika Singh, et al.
Published: (2020-01-01) -
EU Registries Forum Meeting is a new step in the development of international cooperation in rheumatic diseases registries
by: D. E. Karateev
Published: (2015-06-01)